166 related articles for article (PubMed ID: 31193718)
1. An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate
Del Papa J; Petryk J; Bell JC; Parks RJ
Mol Ther Oncolytics; 2019 Sep; 14():107-120. PubMed ID: 31193718
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer.
Wong CM; Poulin KL; Tong G; Christou C; Kennedy MA; Falls T; Bell JC; Parks RJ
PLoS One; 2016; 11(3):e0151516. PubMed ID: 26986751
[TBL] [Abstract][Full Text] [Related]
3. Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.
Le Boeuf F; Gebremeskel S; McMullen N; He H; Greenshields AL; Hoskin DW; Bell JC; Johnston B; Pan C; Duncan R
Mol Ther Oncolytics; 2017 Sep; 6():80-89. PubMed ID: 28856238
[TBL] [Abstract][Full Text] [Related]
4. Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer.
Wong CM; Nash LA; Del Papa J; Poulin KL; Falls T; Bell JC; Parks RJ
Cancer Gene Ther; 2016 Oct; 23(10):355-364. PubMed ID: 27740615
[TBL] [Abstract][Full Text] [Related]
5. The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector.
Clarkin RG; Del Papa J; Poulin KL; Parks RJ
Virology; 2021 Sep; 561():87-97. PubMed ID: 34171766
[TBL] [Abstract][Full Text] [Related]
6. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
7. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
8. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
10. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.
Guedan S; Grases D; Rojas JJ; Gros A; Vilardell F; Vile R; Mercade E; Cascallo M; Alemany R
Gene Ther; 2012 Nov; 19(11):1048-57. PubMed ID: 22113313
[TBL] [Abstract][Full Text] [Related]
11. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
12. Production of a replicating retroviral vector expressing Reovirus fast protein for cancer gene therapy.
Jeon YH; Jung YT
J Virol Methods; 2022 Jan; 299():114332. PubMed ID: 34655690
[TBL] [Abstract][Full Text] [Related]
13. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
Thomas MA; Spencer JF; La Regina MC; Dhar D; Tollefson AE; Toth K; Wold WS
Cancer Res; 2006 Feb; 66(3):1270-6. PubMed ID: 16452178
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters.
Hasegawa N; Abei M; Yokoyama KK; Fukuda K; Seo E; Kawashima R; Nakano Y; Yamada T; Nakade K; Hamada H; Obata Y; Hyodo I
Int J Cancer; 2013 Sep; 133(6):1479-88. PubMed ID: 23444104
[TBL] [Abstract][Full Text] [Related]
15. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
16. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer.
Muhammad T; Sakhawat A; Khan AA; Ma L; Gjerset RA; Huang Y
Stem Cell Res Ther; 2019 Jun; 10(1):190. PubMed ID: 31238944
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.
Zhang R; Zhang X; Ma B; Xiao B; Huang F; Huang P; Ying C; Liu T; Wang Y
Cancer Gene Ther; 2016 Jun; 23(6):168-77. PubMed ID: 27080225
[TBL] [Abstract][Full Text] [Related]
19. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
Wang Q; Yang M; Zhang Y; Zhong L; Zheng X
Curr Gene Ther; 2019; 19(1):54-65. PubMed ID: 30848201
[TBL] [Abstract][Full Text] [Related]
20. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
